These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 14603608)

  • 1. [Pain therapy in patients with tumors. According to graduated schedule and hourly plan].
    MMW Fortschr Med; 2003 Oct; 145(40):53. PubMed ID: 14603608
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pain therapy with semisynthetic opioids. Patients have opioid-type side effects more rarely].
    Sohn W
    MMW Fortschr Med; 2003 Jul; 145(27-28):50. PubMed ID: 14587190
    [No Abstract]   [Full Text] [Related]  

  • 3. Hydromorphone-OROS formulation.
    Goforth HW
    Expert Opin Pharmacother; 2010 May; 11(7):1207-14. PubMed ID: 20402557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Delayed action and rapidly effective in combination. Hydromorphone--already a WHO stage 3 drug].
    MMW Fortschr Med; 2006 May; 148(19):47. PubMed ID: 16736708
    [No Abstract]   [Full Text] [Related]  

  • 5. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
    Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
    Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial.
    Chang AK; Bijur PE; Baccelieri A; Gallagher EJ
    Am J Geriatr Pharmacother; 2009 Feb; 7(1):1-10. PubMed ID: 19281935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transitioning a cancer patient from high-dose intravenous hydromorphone therapy to intravenous methadone.
    LeBaron V; Brody J; Lee EM; Hardin C; Snyder L
    J Pain Palliat Care Pharmacother; 2011; 25(4):356-61. PubMed ID: 22126165
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pain reduced and quality of life improved by sustained-release hydromorphone. Results of an observational study].
    Sittig HB
    MMW Fortschr Med; 2004 Dec; 146(Suppl 3-4):95-8. PubMed ID: 15662898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
    Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
    Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pain therapy. Extensive possibilities not adequately utilized].
    MMW Fortschr Med; 2005 May; 147(19):60-1. PubMed ID: 15940943
    [No Abstract]   [Full Text] [Related]  

  • 11. [Observational data in elderly pain patients show that fear of opioid therapy is unfounded].
    Junker U; Figge V
    MMW Fortschr Med; 2005 Jul; 147(27-28):43. PubMed ID: 16041941
    [No Abstract]   [Full Text] [Related]  

  • 12. [Controlled-release hydromorphone in elderly patients with severe pain of different etiologies. Results of an observational study].
    Junker U; Figge V
    MMW Fortschr Med; 2005 Oct; 147 Suppl 3():91-6. PubMed ID: 16261943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pain reduced and quality of life improved by sustained-release hydromorphone. Results of an observational study].
    Sittig HB
    MMW Fortschr Med; 2004 Dec; 146(49):45. PubMed ID: 15646717
    [No Abstract]   [Full Text] [Related]  

  • 14. Outcomes after intravenous opioids in emergency patients: a prospective cohort analysis.
    O'Connor AB; Zwemer FL; Hays DP; Feng C
    Acad Emerg Med; 2009 Jun; 16(6):477-87. PubMed ID: 19426295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid conversion guidelines for managing adult cancer pain.
    Derby SA
    Am J Nurs; 1999 Oct; 99(10):62-5. PubMed ID: 10542852
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral hydromorphone extended-release.
    Guay DR
    Consult Pharm; 2010 Dec; 25(12):816-28. PubMed ID: 21172762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary adrenal failure and secondary amenorrhoea following hydromorphone treatment.
    Müssig K; Knaus-Dittmann D; Schmidt H; Mörike K; Häring HU
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):604-5. PubMed ID: 17371484
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials.
    Grosset AB; Roberts MS; Woodson ME; Shi M; Swanton RE; Reder RF; Buckley BJ
    J Pain Symptom Manage; 2005 Jun; 29(6):584-94. PubMed ID: 15963867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exceptionally high narcotic analgesic requirements in a terminally ill cancer patient.
    Lo SL; Coleman RR
    Clin Pharm; 1986 Oct; 5(10):828-32. PubMed ID: 2430752
    [No Abstract]   [Full Text] [Related]  

  • 20. The metamorphosis of hydromorphone.
    Reisfield GM; Wilson GR
    J Opioid Manag; 2005; 1(3):139-45. PubMed ID: 17315417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.